重庆智翔金泰生物制药股份有限公司 自愿披露关于赛立奇单抗注射液纳入2025年国家医保目录的公告

Group 1 - The company’s product, Secuquimab injection (Jinlixi), has been successfully included in the National Medical Insurance Directory, effective from January 1, 2026 [1][2] - Secuquimab is a recombinant fully human anti-IL-17A monoclonal antibody, classified as a Class I therapeutic biological product, targeting IL-17A to treat autoimmune diseases [2] - The product has received approval for treating moderate to severe plaque psoriasis in adults and ankylosing spondylitis (radiographic axial spondyloarthritis) in adults, marking it as the first domestic IL-17A inhibitor approved for these indications [2] Group 2 - The inclusion in the National Medical Insurance Directory reflects the recognition and support from the National Healthcare Security Administration for innovative drugs with high clinical value and patient benefits [3] - The new National Medical Insurance Directory will officially implement on January 1, 2026, with specific reimbursement standards and details to be announced by relevant government departments [3]